349 related articles for article (PubMed ID: 25578041)
21. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
22. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
23. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.
Yamasaki T; Kamba T; Kanno T; Inoue T; Shibasaki N; Arakaki R; Yamada T; Kondo K; Kamoto T; Nishiyama H; Ogawa O; Nakamura E
Cancer Sci; 2012 Nov; 103(11):2027-37. PubMed ID: 22931246
[TBL] [Abstract][Full Text] [Related]
24. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
Raval RR; Lau KW; Tran MG; Sowter HM; Mandriota SJ; Li JL; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Mol Cell Biol; 2005 Jul; 25(13):5675-86. PubMed ID: 15964822
[TBL] [Abstract][Full Text] [Related]
25. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
26. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
27. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.
Zhai W; Sun Y; Jiang M; Wang M; Gasiewicz TA; Zheng J; Chang C
Oncogene; 2016 Sep; 35(37):4866-80. PubMed ID: 26973243
[TBL] [Abstract][Full Text] [Related]
29. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
30. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
[TBL] [Abstract][Full Text] [Related]
31. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
32. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
33. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
35. Antitumor and antiangiogenic activity of Schisandra chinensis polysaccharide in a renal cell carcinoma model.
Qu HM; Liu SJ; Zhang CY
Int J Biol Macromol; 2014 May; 66():52-6. PubMed ID: 24556120
[TBL] [Abstract][Full Text] [Related]
36. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
37. JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
Wu KL; Miao H; Khan S
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1836-46. PubMed ID: 17898043
[TBL] [Abstract][Full Text] [Related]
38. Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
Fu R; Chen Y; Wang XP; An T; Tao L; Zhou YX; Huang YJ; Chen BA; Li ZY; You QD; Guo QL; Wu ZQ
Oncotarget; 2016 Feb; 7(5):5715-27. PubMed ID: 26735336
[TBL] [Abstract][Full Text] [Related]
39. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
40. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
